86 related articles for article (PubMed ID: 19010092)
1. Quantitative proteomic analysis of follicular lymphoma cells in response to rituximab.
Everton KL; Abbott DR; Crockett DK; Elenitoba-Johnson KS; Lim MS
J Chromatogr B Analyt Technol Biomed Life Sci; 2009 May; 877(13):1335-43. PubMed ID: 19010092
[TBL] [Abstract][Full Text] [Related]
2. Responses to rituximab vary among follicular lymphoma B cells of different maturation stages.
Mattila AM; Meri S
Scand J Immunol; 2008 Aug; 68(2):159-68. PubMed ID: 18702746
[TBL] [Abstract][Full Text] [Related]
3. Acquirement of rituximab resistance in lymphoma cell lines is associated with both global CD20 gene and protein down-regulation regulated at the pretranscriptional and posttranscriptional levels.
Czuczman MS; Olejniczak S; Gowda A; Kotowski A; Binder A; Kaur H; Knight J; Starostik P; Deans J; Hernandez-Ilizaliturri FJ
Clin Cancer Res; 2008 Mar; 14(5):1561-70. PubMed ID: 18316581
[TBL] [Abstract][Full Text] [Related]
4. The involvement of mitochondria and the caspase-9 activation pathway in rituximab-induced apoptosis in FL cells.
Eeva J; Nuutinen U; Ropponen A; Mättö M; Eray M; Pellinen R; Wahlfors J; Pelkonen J
Apoptosis; 2009 May; 14(5):687-98. PubMed ID: 19308735
[TBL] [Abstract][Full Text] [Related]
5. An imaging-based rapid evaluation method for complement-dependent cytotoxicity discriminated clinical response to rituximab-containing chemotherapy.
Mishima Y; Sugimura N; Matsumoto-Mishima Y; Terui Y; Takeuchi K; Asai S; Ennishi D; Asai H; Yokoyama M; Kojima K; Hatake K
Clin Cancer Res; 2009 May; 15(10):3624-32. PubMed ID: 19417028
[TBL] [Abstract][Full Text] [Related]
6. CpG ODN enhances the efficacy of rituximab in non-Hodgkin lymphoma.
Buhé V; Guerrier T; Youinou P; Berthou C; Loisel S
Ann N Y Acad Sci; 2009 Sep; 1173():858-64. PubMed ID: 19758238
[TBL] [Abstract][Full Text] [Related]
7. Cholesterol depletion inhibits src family kinase-dependent calcium mobilization and apoptosis induced by rituximab crosslinking.
Unruh TL; Li H; Mutch CM; Shariat N; Grigoriou L; Sanyal R; Brown CB; Deans JP
Immunology; 2005 Oct; 116(2):223-32. PubMed ID: 16162271
[TBL] [Abstract][Full Text] [Related]
8. Temporal and spatial profiling of nuclei-associated proteins upon TNF-alpha/NF-kappaB signaling.
Ma DJ; Li SJ; Wang LS; Dai J; Zhao SL; Zeng R
Cell Res; 2009 May; 19(5):651-64. PubMed ID: 19399029
[TBL] [Abstract][Full Text] [Related]
9. PDTC enables type I TRAIL signaling in type II follicular lymphoma cells.
Nuutinen U; Simelius N; Ropponen A; Eeva J; Mättö M; Eray M; Pellinen R; Wahlfors J; Pelkonen J
Leuk Res; 2009 Jun; 33(6):829-36. PubMed ID: 18977530
[TBL] [Abstract][Full Text] [Related]
10. M2 macrophages phagocytose rituximab-opsonized leukemic targets more efficiently than m1 cells in vitro.
Leidi M; Gotti E; Bologna L; Miranda E; Rimoldi M; Sica A; Roncalli M; Palumbo GA; Introna M; Golay J
J Immunol; 2009 Apr; 182(7):4415-22. PubMed ID: 19299742
[TBL] [Abstract][Full Text] [Related]
11. Rituximab-mediated cell signaling and chemo/immuno-sensitization of drug-resistant B-NHL is independent of its Fc functions.
Vega MI; Huerta-Yepez S; Martinez-Paniagua M; Martinez-Miguel B; Hernandez-Pando R; González-Bonilla CR; Chinn P; Hanna N; Hariharan K; Jazirehi AR; Bonavida B
Clin Cancer Res; 2009 Nov; 15(21):6582-94. PubMed ID: 19861448
[TBL] [Abstract][Full Text] [Related]
12. NK cell-mediated lysis is essential to kill Epstein-Barr virus transformed lymphoblastoid B cells when using rituximab.
Markasz L; Vanherberghen B; Flaberg E; Otvös R; Stuber G; Gustafsson Jernberg A; Olah E; Skribek H; Szekely L
Biomed Pharmacother; 2009 Jul; 63(6):413-20. PubMed ID: 18834693
[TBL] [Abstract][Full Text] [Related]
13. Different signaling pathways expressed by chicken naive CD4(+) T cells, CD4(+) lymphocytes activated with staphylococcal enterotoxin B, and those malignantly transformed by Marek's disease virus.
Buza JJ; Burgess SC
J Proteome Res; 2008 Jun; 7(6):2380-7. PubMed ID: 18412384
[TBL] [Abstract][Full Text] [Related]
14. The role of complement in the mechanism of action of rituximab for B-cell lymphoma: implications for therapy.
Zhou X; Hu W; Qin X
Oncologist; 2008 Sep; 13(9):954-66. PubMed ID: 18779537
[TBL] [Abstract][Full Text] [Related]
15. Identification of CD20 C-terminal deletion mutations associated with loss of CD20 expression in non-Hodgkin's lymphoma.
Terui Y; Mishima Y; Sugimura N; Kojima K; Sakurai T; Mishima Y; Kuniyoshi R; Taniyama A; Yokoyama M; Sakajiri S; Takeuchi K; Watanabe C; Takahashi S; Ito Y; Hatake K
Clin Cancer Res; 2009 Apr; 15(7):2523-30. PubMed ID: 19276251
[TBL] [Abstract][Full Text] [Related]
16. [Rituximab resistance in B-cell lymphoma and its elimination].
Hatake K; Terui Y
Gan To Kagaku Ryoho; 2009 Apr; 36(4):548-51. PubMed ID: 19381025
[TBL] [Abstract][Full Text] [Related]
17. In vivo model of follicular lymphoma resistant to rituximab.
Dalle S; Dupire S; Brunet-Manquat S; Reslan L; Plesa A; Dumontet C
Clin Cancer Res; 2009 Feb; 15(3):851-7. PubMed ID: 19188155
[TBL] [Abstract][Full Text] [Related]
18. Proteomic analysis identifies oxidative stress induction by adaphostin.
Stockwin LH; Bumke MA; Yu SX; Webb SP; Collins JR; Hollingshead MG; Newton DL
Clin Cancer Res; 2007 Jun; 13(12):3667-81. PubMed ID: 17575232
[TBL] [Abstract][Full Text] [Related]
19. [Cutaneous follicular center B-cell lymphoma treated with intralesional rituximab].
Gamo R; Calzado L; Pinedo F; López-Estebaranz JL
Actas Dermosifiliogr; 2008 May; 99(4):291-6. PubMed ID: 18394405
[TBL] [Abstract][Full Text] [Related]
20. Proteomic analysis of the resistance to aplidin in human cancer cells.
González-Santiago L; Alfonso P; Suárez Y; Núñez A; García-Fernández LF; Alvarez E; Muñoz A; Casal JI
J Proteome Res; 2007 Apr; 6(4):1286-94. PubMed ID: 17338558
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
